• Higher ALT increase in Nasvac-treated than Peg-IFN treated subjects (85 vs. 30%), after 5 nasal vaccinations in subjects with chronic hepatitis B • Superior reduction of the viral load under the limit of detection, by Nasvac treatment compared to Peg-IFN treatment • Lower progression to cirrhosis in Nasvac group compared to Peg-IFN group • Nasvac significantly safer compared to Peg-IFN in all major variables related to AE. The gene discussed is IFNA1; the disease is Cirrhosis.